Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia

Overview

Journal Cancer Res

Specialty Oncology

Date 2024 Jan 19

PMID 38241703

Authors

Franca Raucci

Claudio Vernieri

Maira Di Tano

Francesca Ligorio

Olga Blazevits

Samuel Lazzeri

Anastasiya Shmahala

Giuseppe Fragale

Giulia Salvadori

Gabriele Varano

Stefano Casola

Roberta Buono

Euplio Visco

Filippo De Braud

Valter D Longo

Affiliations

Soon will be listed here.

Abstract

Significance: Chronic lymphocytic leukemia cells resist fasting-mimicking diet by inducing proteasome activation to escape starvation, which can be targeted using proteasome inhibition by bortezomib treatment to impede leukemia progression and prolong survival.

Citing Articles

Fasting as an Adjuvant Therapy for Cancer: Mechanism of Action and Clinical Practice.

Xie Y, Ye H, Liu Z, Liang Z, Zhu J, Zhang R Biomolecules. 2024; 14(11).

PMID: 39595613 PMC: 11591922. DOI: 10.3390/biom14111437.

Nutritional modulation of antitumor immunity.

Jeong M, Collins N Curr Opin Immunol. 2024; 87:102422.

PMID: 38728931 PMC: 11288377. DOI: 10.1016/j.coi.2024.102422.

References

Tam C, Robak T, Ghia P, Kahl B, Walker P, Janowski W . Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020; 106(9):2354-2363. PMC: 8409041. DOI: 10.3324/haematol.2020.259432. View

Rozovski U, Hazan-Halevy I, Barzilai M, Keating M, Estrov Z . Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 57(4):758-65. PMC: 4794359. DOI: 10.3109/10428194.2015.1106533. View

Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K . Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat Cancer. 2022; 1(1):75-85. DOI: 10.1038/s43018-019-0007-9. View

Tsai H, Cross A, Graubard B, Oken M, Schatzkin A, Caporaso N . Dietary factors and risk of chronic lymphocytic leukemia and small lymphocytic lymphoma: a pooled analysis of two prospective studies. Cancer Epidemiol Biomarkers Prev. 2010; 19(10):2680-4. PMC: 3501724. DOI: 10.1158/1055-9965.EPI-10-0585. View

Ligorio F, Fuca G, Provenzano L, Lobefaro R, Zanenga L, Vingiani A . Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. Eur J Cancer. 2022; 172:300-310. DOI: 10.1016/j.ejca.2022.05.046. View

Cory A, Chen J, Cory J . Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Anticancer Res. 2006; 26(2A):1289-95. View

Pozzo F, Dal Bo M, Peragine N, Bomben R, Zucchetto A, Rossi F . Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. J Hematol Oncol. 2013; 6:83. PMC: 4222122. DOI: 10.1186/1756-8722-6-83. View

Lara S, Heilig J, Virtanen A, Kleinau S . Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma. BMC Cancer. 2022; 22(1):678. PMC: 9210731. DOI: 10.1186/s12885-022-09772-1. View

Zinzani P, Khuageva N, Wang H, Garicochea B, Walewski J, Van Hoof A . Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012; 5:67. PMC: 3502148. DOI: 10.1186/1756-8722-5-67. View

10.

Lee C, Raffaghello L, Brandhorst S, Safdie F, Bianchi G, Martin-Montalvo A . Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012; 4(124):124ra27. PMC: 3608686. DOI: 10.1126/scitranslmed.3003293. View

11.

Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E . Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003; 171(3):1581-7. DOI: 10.4049/jimmunol.171.3.1581. View

12.

Fan W, Wang F, Lu Z, Pan Z, Li L, Gao Y . Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial. Chin J Cancer. 2015; 34(9):394-403. PMC: 4593338. DOI: 10.1186/s40880-015-0024-8. View

13.

Brandhorst S, Choi I, Wei M, Cheng C, Sedrakyan S, Navarrete G . A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015; 22(1):86-99. PMC: 4509734. DOI: 10.1016/j.cmet.2015.05.012. View

14.

Brandhorst S, Wei M, Hwang S, Morgan T, Longo V . Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol. 2013; 48(10):1120-8. PMC: 3762887. DOI: 10.1016/j.exger.2013.02.016. View

15.

Ling Y, Liebes L, Jiang J, Holland J, Elliott P, Adams J . Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003; 9(3):1145-54. View

16.

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

17.

Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W . Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2016; 23(1):79-90. PMC: 6956990. DOI: 10.1038/nm.4252. View

18.

Chiorazzi N, Rai K, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-15. DOI: 10.1056/NEJMra041720. View

19.

Stolz C, Hess G, Hahnel P, Grabellus F, Hoffarth S, Schmid K . Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008; 112(8):3312-21. DOI: 10.1182/blood-2007-11-124487. View

20.

Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291. PMC: 8151619. DOI: 10.1016/S0140-6736(20)30262-2. View